Sera Prognostics(US:SERA)2026-03-18 22:02Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $10,000, down from $24,000 in Q4 2024, reflecting modest revenue fluctuations typical in early commercial stages [20] - Total revenue for 2025 was $81,000, slightly up from $77,000 in 2024, indicating a gradual revenue expansion [21] - Operating expenses for Q4 2025 were $9 million, down from $9.4 million in the prior year, showcasing disciplined expense management [20] - Net loss for Q4 2025 was $7.9 million compared to a net loss of $8.6 million in Q4 2024, demonstrating improved financial control [21] Business Line Data and Key Metrics Changes - Research and development expenses for 2025 were $13.2 million, down from $14.7 million in 2024, driven by lower clinical study costs following the completion of the PRIME study [21] - Selling, general, and administrative expenses were $23.3 million compared to $21.9 million in the previous year, reflecting targeted commercial readiness investments [21] Market Data and Key Metrics Changes - The company engaged with 13 states for partner programs, exceeding its initial goal of six states, and aims to expand to 15-17 states by year-end 2026 [9] - In Europe, the company is working towards CE marking approval for its preterm global test, with submissions expected in the coming months [10] Company Strategy and Development Direction - The company aims to build evidence, access, and commercial infrastructure to drive preterm birth adoption at scale, with a focus on Medicaid and high preterm birth burden states [5][8] - A disciplined approach to market access and commercial infrastructure investments is being maintained, with a focus on expanding partner programs and generating real-world evidence [11][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum gained from the PRIME publication and the growing engagement with payers and state-level stakeholders [45] - The company anticipates gradual adoption of its technology, supported by compelling clinical evidence and increasing payer engagement [45] Other Important Information - The company ended 2025 with $95.8 million in cash equivalents, which is expected to fund operations through significant adoption and commercial milestones until 2028 [22][25] - A new Head of Sales and Strategic Accounts has been appointed to enhance commercial execution and market access [15] Q&A Session Summary Question: Can you expand on converting payer discussions and partner programs using outcomes and economic data? - The company highlighted the importance of clinical outcomes and economic benefits in discussions with partners, particularly for state Medicaid agencies [29] - The reduction in NICU admissions is a significant cost driver that partners are interested in [30] Question: What feedback was received at the SMFM conference regarding PRIME? - Engagement with providers and leadership at SMFM was strong, focusing on making the test more accessible [33] - The publication has improved credibility and engagement across various stakeholders [35] Question: How will the company balance investments in successful U.S. states versus global EU launch capital requirements? - The company plans to reallocate spending from clinical and R&D activities towards commercial activities, including EU opportunities [38] Question: Can you elaborate on the profile of the new partner? - The company is negotiating with large health systems, provider payers, and group practices, aiming to implement the PreTRM test as standard care [40] - The new partner is an employer collaborative with multi-state opportunities [42]